DIAGNOS Announces the Opening of Two New Screening Clinics in Hafar al-Batin, to Screen 10,000 Patients in the next Six Month...
May 30 2019 - 10:00AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK),
(OTCQB: DGNOD), a leader in early detection of critical health
issues through the use of Artificial Intelligence (AI), announces
today the opening of two screening clinics in Hafar al-Batin in
Saudi Arabia with its partner Kanhoor Medical Co. (“Kanhoor”) for
10,000 patients in the next 6 months.
Following the conclusion of a successful trial,
Kanhoor is pleased to have signed these two agreements with 2
regional hospitals to screen diabetic patients.
“We are excited to continue our collaboration
with Kanhoor. These 2 contracts are another successful
demonstration of our strategy to work with Kanhoor as our business
partner. We continue to work with them to grow our revenue
and market share in Saudi Arabia”, said Yves-Stéphane Couture,
Vice-president of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements.DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024